Short delay in initiation of radiotherapy for patients with glioblastoma-effect of concurrent chemotherapy: A secondary analysis from the NRG Oncology/Radiation Therapy Oncology Group database

Deborah T. Blumenthal, Minhee Won, Minesh P. Mehta, Mark R. Gilbert, Paul D. Brown, Felix Bokstein, David G. Brachman, Maria Werner-Wasik, Grant K. Hunter, Egils Valeinis, Kirsten Hopkins, Luis Souhami, Steven P. Howard, Frank S. Lieberman, Dennis C. Shrieve, Merideth M. Wendland, Cliff G. Robinson, Peixin Zhang, Benjamin W. Corn

Research output: Contribution to journalArticle

11 Scopus citations

Abstract

Background We previously reported the unexpected finding of significantly improved survival for newly diagnosed glioblastoma in patients when radiation therapy (RT) was initiated later (>4 wk post-op) compared with earlier (≤2 wk post-op). In that analysis, data were analyzed from 2855 patients from 16 NRG Oncology/Radiotherapy Oncology Group (RTOG) trials conducted prior to the era of concurrent temozolomide (TMZ) with RT. We now report on 1395 newly diagnosed glioblastomas from 2 studies, treated with RT and concurrent TMZ followed by adjuvant TMZ. Our hypothesis was that concurrent TMZ has a synergistic/radiosensitizing mechanism, making RT timing less significant. Methods Data from patients treated with TMZ-based chemoradiation from NRG Oncology/RTOG 0525 and 0825 were analyzed. An analysis comparable to our prior study was performed to determine whether there was still an impact on survival by delaying RT. Overall survival (OS) was investigated using the Kaplan-Meier method and Cox proportional hazards model. Early progression (during time of diagnosis to 30 days after RT completion) was analyzed using the chi-square test. Results Given the small number of patients who started RT early following surgery, comparisons were made between >4 and ≤4 weeks delay of radiation from time of operation. There was no statistically significant difference in OS (hazard ratio = 0.93; P = 0.29; 95% CI: 0.80-1.07) after adjusting for known prognostic factors (recursive partitioning analysis and O 6 -methylguanine-DNA methyltransferase methylation status). Similarly, the rate of early progression did not differ significantly (P = 0.63). Conclusions We did not observe a significant prognostic influence of delaying radiation when given concurrently with TMZ for newly diagnosed glioblastoma. The effects of early (1-3 wk post-op) or late (>5 wk) initiation of radiation tested in our prior study could not be replicated.

Original languageEnglish
Pages (from-to)966-974
Number of pages9
JournalNeuro-oncology
Volume20
Issue number7
DOIs
StatePublished - Jun 18 2018

Keywords

  • chemoradiation
  • delay
  • glioblastoma
  • survival
  • temozolomide

Fingerprint Dive into the research topics of 'Short delay in initiation of radiotherapy for patients with glioblastoma-effect of concurrent chemotherapy: A secondary analysis from the NRG Oncology/Radiation Therapy Oncology Group database'. Together they form a unique fingerprint.

  • Cite this

    Blumenthal, D. T., Won, M., Mehta, M. P., Gilbert, M. R., Brown, P. D., Bokstein, F., Brachman, D. G., Werner-Wasik, M., Hunter, G. K., Valeinis, E., Hopkins, K., Souhami, L., Howard, S. P., Lieberman, F. S., Shrieve, D. C., Wendland, M. M., Robinson, C. G., Zhang, P., & Corn, B. W. (2018). Short delay in initiation of radiotherapy for patients with glioblastoma-effect of concurrent chemotherapy: A secondary analysis from the NRG Oncology/Radiation Therapy Oncology Group database. Neuro-oncology, 20(7), 966-974. https://doi.org/10.1093/neuonc/noy017